








CORRECTION

Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer

Giuseppe Curigliano , Geoffrey I. Shapiro , Rebecca S. Kristeleit , Albiruni R. Abdul Razak, Stephen Leong, Maria Alsina , Antonio Giordano, Karen A. Gelmon, Erica Stringer-Reasor, Ulka N. Vaishampayan, Mark Middleton , Anthony J. Olszanski , Hope S. Rugo , Kenneth A. Kern, Nuzhat Pathan, Rachelle Perea, Kristen J. Pierce, Sarah C. Mutka and Zev A. Wainberg

© The Author(s), under exclusive licence to Springer Nature Limited 2023

British Journal of Cancer (2023) 128:400; <https://doi.org/10.1038/s41416-023-02161-w>

Correction to: *British Journal of Cancer* <https://doi.org/10.1038/s41416-022-02025-9>, published online 5 November 2022

The original version of this article contained an error in an affiliation. As per Italian regulation, the two affiliations for

Dr. Curigliano (Istituto Europeo di Oncologia, IRCCS and University of Milan, Milano, Italy) must be separated out for proper accreditation within their systems. The original article has been corrected.